Definium Therapeutics (DFTX) Other Gross PP&E Adjustments (2019 - 2026)
Definium Therapeutics (DFTX) reported Other Gross PP&E Adjustments of -$2.8 million for Q1 2026, down 96.73% year-over-year from -$86.4 million in Q1 2025, and down 215.87% on a QoQ basis from -$895000.0 in Q4 2025.
Definium Therapeutics (DFTX) has 8 years of Other Gross PP&E Adjustments data on file, last reported at -$2.8 million in Q1 2026.
- Quarterly Other Gross PP&E Adjustments fell 96.73% year-over-year to -$2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.3 million (down 6.53% YoY) and the FY2025 annual result came in at -$895000.0, up 66.25% from the prior year.
- Other Gross PP&E Adjustments declined to -$2.8 million in Q1 2026 per DFTX's latest filing, from -$895000.0 in the prior quarter.
- Across five years, Other Gross PP&E Adjustments topped out at -$895000.0 in Q4 2025 and bottomed at -$2.8 million in Q1 2026.
- The 5-year median for Other Gross PP&E Adjustments is -$1.6 million (2022), against an average of -$1.7 million.
- The widest annual swing landed in 2022, when Other Gross PP&E Adjustments sank 2955.32%; it then surged 66.25% in 2025.
- Tracing DFTX's Other Gross PP&E Adjustments over 5 years: stood at -$1.6 million in 2022, then retreated by 24.97% to -$2.0 million in 2023, then plunged by 31.16% to -$2.7 million in 2024, then surged by 66.25% to -$895000.0 in 2025, then sank by 215.87% to -$2.8 million in 2026.
- Per Business Quant, the three latest DFTX Other Gross PP&E Adjustments figures stand at -$2.8 million (Q1 2026), -$895000.0 (Q4 2025), and -$1.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Gross PP&E Adjustments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -83,048.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -60,691.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -285.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -892,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -1.69 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -189.30 Mn |
| 10 | Definium Therapeutics | 2.42 Bn | 2.06 Bn | - | -2.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.83 Mn |
| Mar 31, 2026 | -2.83 Mn |
| Dec 31, 2025 | -895,000.00 |
| Dec 31, 2025 | -895,000.00 |
| Sep 30, 2025 | -1.69 Mn |
| Sep 30, 2025 | -1.69 Mn |
| Jun 30, 2025 | -1.89 Mn |
| Jun 30, 2025 | -1.89 Mn |
| Mar 31, 2025 | -1.44 Mn |
| Mar 31, 2025 | -1.44 Mn |
| Dec 31, 2024 | -2.65 Mn |
| Dec 31, 2024 | -2.65 Mn |
| Sep 30, 2024 | -1.31 Mn |
| Sep 30, 2024 | -1.31 Mn |
| Jun 30, 2024 | -1.45 Mn |
| Jun 30, 2024 | -1.45 Mn |
| Mar 31, 2024 | -2.49 Mn |
| Mar 31, 2024 | -2.49 Mn |
| Dec 31, 2023 | -2.02 Mn |
| Dec 31, 2023 | -2.02 Mn |
| Sep 30, 2023 | -1.13 Mn |
| Sep 30, 2023 | -1.13 Mn |
| Jun 30, 2023 | -1.87 Mn |
| Jun 30, 2023 | -1.87 Mn |
| Mar 31, 2023 | -1.41 Mn |
| Mar 31, 2023 | -1.41 Mn |
| Dec 31, 2022 | -1.62 Mn |
| Dec 31, 2022 | -1.62 Mn |
| Sep 30, 2022 | -1.44 Mn |
| Sep 30, 2022 | -1.44 Mn |
| Jun 30, 2022 | -1.60 Mn |
| Jun 30, 2022 | -1.60 Mn |
| Mar 31, 2022 | -1.70 Mn |
| Mar 31, 2022 | -1.70 Mn |
| Dec 31, 2021 | -4.41 Mn |
| Dec 31, 2021 | -4.41 Mn |
| Sep 30, 2021 | -47,000.00 |
| Sep 30, 2021 | -47,000.00 |
| Jun 30, 2021 | -1.21 Mn |
| Jun 30, 2021 | -1.21 Mn |
| Mar 31, 2021 | -1.17 Mn |
| Mar 31, 2021 | -1.17 Mn |
| Dec 31, 2020 | -988,000.00 |
| Dec 31, 2020 | -988,000.00 |
| Sep 30, 2020 | -144,000.00 |
| Sep 30, 2020 | -144,000.00 |
| Jun 30, 2020 | -231,000.00 |
| Jun 30, 2020 | -231,000.00 |
| Mar 31, 2020 | -31,000.00 |
| Mar 31, 2020 | -31,000.00 |
| Dec 31, 2019 | -1.05 Mn |
| Dec 31, 2019 | -1.05 Mn |